These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 32636149

  • 21. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
    Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F.
    Cancer; 2009 Jan 01; 115(1):101-6. PubMed ID: 19090005
    [Abstract] [Full Text] [Related]

  • 22. The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia.
    Jabbour E, Kantarjian H.
    Clin Lymphoma Myeloma Leuk; 2021 Jan 01; 21(1):63-65. PubMed ID: 33191168
    [No Abstract] [Full Text] [Related]

  • 23. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S.
    Haematologica; 2015 May 01; 100(5):653-61. PubMed ID: 25682595
    [Abstract] [Full Text] [Related]

  • 24. High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden.
    Kozlowski P, Åström M, Ahlberg L, Bernell P, Hulegårdh E, Hägglund H, Karlsson K, Markuszewska-Kuczymska A, Tomaszewska-Toporska B, Smedmyr B, Amini RM, Hallböök H, Swedish Adult ALL Group.
    Eur J Haematol; 2014 May 01; 92(5):377-81. PubMed ID: 24443846
    [Abstract] [Full Text] [Related]

  • 25. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
    Othman T, Moskoff BN, Ho G, Tenold ME, Azenkot T, Krackeler ML, Fisch SC, Potter LA, Kaesberg PR, Welborn JL, Wun T, Esteghamat NS, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA.
    Leuk Res; 2022 Aug 01; 119():106885. PubMed ID: 35738024
    [Abstract] [Full Text] [Related]

  • 26. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
    Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H.
    Blood; 2004 Sep 15; 104(6):1624-30. PubMed ID: 15178574
    [Abstract] [Full Text] [Related]

  • 27. Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
    Erkut N, Akidan O, Selim Batur D, Karabacak V, Sonmez M.
    Chemotherapy; 2018 Sep 15; 63(4):207-213. PubMed ID: 30304722
    [Abstract] [Full Text] [Related]

  • 28. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
    Garg R, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D, Pierce S, O'Brien S.
    Cancer; 2009 May 15; 115(10):2147-54. PubMed ID: 19298009
    [Abstract] [Full Text] [Related]

  • 29. Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Kodama Y, Manabe A, Kawasaki H, Kato I, Kato K, Sato A, Matsumoto K, Kato M, Hiramatsu H, Sano H, Kaneko T, Oda M, Saito AM, Adachi S, Horibe K, Mizutani S, Ishii E, Shimada H.
    Pediatr Blood Cancer; 2017 Aug 15; 64(8):. PubMed ID: 28084041
    [Abstract] [Full Text] [Related]

  • 30. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
    O'Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H.
    Cancer; 2008 Oct 15; 113(8):2097-101. PubMed ID: 18720356
    [Abstract] [Full Text] [Related]

  • 31. [A clinical report on modified Hyper-CVAD regimen in patients with lymphoblastic lymphoma].
    Shi W, Shi YK, He XH, Zhou SY, Dong M, Zhang CG, Yang JL, Liu P, Qin Y, Yang S, Gui L.
    Zhonghua Yi Xue Za Zhi; 2010 Apr 13; 90(14):978-81. PubMed ID: 20646648
    [Abstract] [Full Text] [Related]

  • 32. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F, Balabanov S, Soldini D, Samaras P, Gerber B, Manz MG, Goede JS.
    Ann Hematol; 2018 Feb 13; 97(2):277-287. PubMed ID: 29147847
    [Abstract] [Full Text] [Related]

  • 33. Outcome of young adult patients with very-high-risk acute lymphoblastic leukemia treated with pediatric-type chemotherapy - a single institute experience.
    Cheng CN, Li SS, Hsu YT, Chen YP, Chen TY, Chen JS.
    J Formos Med Assoc; 2022 Mar 13; 121(3):694-702. PubMed ID: 34340890
    [Abstract] [Full Text] [Related]

  • 34. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
    Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ.
    Cancer; 2021 Sep 15; 127(18):3381-3389. PubMed ID: 34138471
    [Abstract] [Full Text] [Related]

  • 35. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
    Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H.
    Lancet Haematol; 2018 Dec 15; 5(12):e618-e627. PubMed ID: 30501869
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
    Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM.
    Am J Hematol; 2016 Aug 15; 91(8):819-23. PubMed ID: 27178680
    [Abstract] [Full Text] [Related]

  • 39. The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
    Alabdulwahab AS, Elsayed HG, Sherisher MA, Zeeneldin A, Alghamdi K, Elbjeirami WM.
    Leuk Res; 2017 Sep 15; 60():58-62. PubMed ID: 28704720
    [Abstract] [Full Text] [Related]

  • 40. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
    Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S, Kantarjian H.
    Cancer; 2002 Mar 01; 94(5):1492-9. PubMed ID: 11920506
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.